SCHEMBL24089980

SCHEMBL24089980

O=c1c2ccccc2nc(Nc2ccccc2Cl)n1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 2/20 0.51
C1R P00736 1/20 0.51
POLB P06746 2/20 0.48
KMT2A Q03164 2/20 0.47
MAPT P10636 1/20 0.47
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
IDO2 Q6ZQW0 1/20 0.46
KDM4E B2RXH2 3/20 0.46
PDE5A O76074 1/20 0.46
PDE7A Q13946 2/20 0.46
PDE4B Q07343 1/20 0.46
PTGS2 P35354 1/20 0.45
HPGD P15428 2/20 0.45
USP2 O75604 1/20 0.45
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24089999 0.87 MAPT (0.50) ALDH1A1RAB9ASMN1; SMN2NPC1C1R
SCHEMBL23065144 0.87 PDE7A (0.52) ALDH1A1RAB9ASMN1; SMN2NPC1C1R
SCHEMBL23065087 0.87 PIK3CD (0.47) KMT2APDE7APDE4B
SCHEMBL23064692 0.85 TP53 (0.47) TDO2IDO2
SCHEMBL24090139 0.85 TP53 (0.58) RAB9ASMN1; SMN2NPC1KMT2AIDO1
SCHEMBL23065090 0.85 C1R (0.48) SMN1; SMN2C1RPOLBMAPTKDM4E
SCHEMBL23065109 0.82 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2C1R
SCHEMBL23064685 0.78 TP53 (0.53) TDO2IDO2
SCHEMBL23958271 0.78 MAPT (0.43) ALDH1A1RAB9ANPC1POLBKMT2A
SCHEMBL24110933 0.77 MAPT (0.41) ALDH1A1RAB9ANPC1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL ALDH1A1 645/4885RAB9A 1045/4885SMN1; SMN2 2556/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 ALDH1A1 739/4885RAB9A 902/4885SMN1; SMN2 2469/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 ALDH1A1 739/4885RAB9A 902/4885SMN1; SMN2 2469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.